Curanex Pharmaceuticals Files 8-K
Ticker: CURX · Form: 8-K · Filed: Sep 12, 2025 · CIK: 2025942
| Field | Detail |
|---|---|
| Company | Curanex Pharmaceuticals Inc (CURX) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $4.00, $15,000,000, $2,250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, reporting, corporate-events
TL;DR
Curanex Pharma filed an 8-K on 9/12/25. Standard reporting.
AI Summary
Curanex Pharmaceuticals Inc. filed an 8-K on September 12, 2025, reporting other events and financial statements. The company, incorporated in Nevada, has its principal executive offices in Jericho, NY.
Why It Matters
This filing indicates ongoing corporate activity and reporting requirements for Curanex Pharmaceuticals Inc., providing transparency to investors.
Risk Assessment
Risk Level: low — This is a routine filing for a current report, not indicating any specific adverse events or significant changes.
Key Players & Entities
- Curanex Pharmaceuticals Inc (company) — Registrant
- September 12, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Jericho, NY (location) — Address of principal executive offices
- 718-673-6078 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this Form 8-K filing for Curanex Pharmaceuticals Inc.?
The Form 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of September 12, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 12, 2025.
In which state is Curanex Pharmaceuticals Inc. incorporated?
Curanex Pharmaceuticals Inc. is incorporated in Nevada.
What is the business address of Curanex Pharmaceuticals Inc.?
The business address is 2 Jericho Plaza, Suite 101B, Jericho, NY 11753.
What is the telephone number listed for Curanex Pharmaceuticals Inc.?
The telephone number listed is (718) 673-6078.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-09-12 14:53:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CURX The Nasdaq Capital M
- $4.00 — Stock"), at a public offering price of $4.00 per share, for gross proceeds of $15,00
- $15,000,000 — $4.00 per share, for gross proceeds of $15,000,000. The Shares were offered by the Company
- $2,250,000 — sulting in additional gross proceeds of $2,250,000. Following the closing of the aforesa
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001493152-25-013167.txt ( ) — 239KB
- curx-20250912.xsd (EX-101.SCH) — 3KB
- curx-20250912_lab.xml (EX-101.LAB) — 33KB
- curx-20250912_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Curanex Pharmaceuticals Inc Date: September 12, 2025 By: /s/ Jun Liu Name: Jun Liu Title: Chief Executive Officer